Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. (Q36897382)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665989%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

review article

1 reference

title

Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665989%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665989%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Torbjörn Ramqvist

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665989%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Tina Dalianis

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665989%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

language of work or name

English

0 references

publication date

1 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665989%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

2 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665989%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665989%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665989%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

997-1007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665989%20AND%20SRC:MED&resulttype=core&format=json

Vaccines against human papillomavirus

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

SV40 pseudovirions as highly efficient vectors for gene transfer and their potential application in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Production of polyomavirus structural protein VP1 in yeast cells and its interaction with cell structures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Self-assembly of purified polyomavirus capsid protein VP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

A controlled trial of a human papillomavirus type 16 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Human hepatitis B vaccine from recombinant yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Virus-like particles as HIV-1 vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Filovirus-like particles as vaccines and discovery tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Recombinant Norwalk virus-like particles given orally to volunteers: phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

VP1 pseudocapsids, but not a glutathione-S-transferase VP1 fusion protein, prevent polyomavirus infection in a T-cell immune deficient experimental mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Human papillomavirus vaccine update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Global control of hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Virus-like particles: designing an effective AIDS vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Assembling the human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Parvovirus B19 empty capsids as antigen carriers for presentation of antigenic determinants of dengue 2 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Determinants of autoantibody induction by conjugated papillomavirus virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Chimeric papillomavirus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Human papillomavirus immortalization and transformation functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Segments of puumala hantavirus nucleocapsid protein inserted into chimeric polyomavirus-derived virus-like particles induce a strong immune response in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Cellular immunity to the Her-2/neu protooncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Yeast-derived human immunodeficiency virus type 1 p55(gag) virus-like particles activate dendritic cells (DCs) and induce perforin expression in Gag-specific CD8(+) T cells by cross-presentation of DCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Virus-like particles derived from major capsid protein VP1 of different polyomaviruses differ in their ability to induce maturation in human dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Gene Transfer by Polyoma-Like Particles Assembled in a Cell-Free System

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Polyoma virus pseudocapsids as efficient carriers of heterologous DNA into mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Packaging of small molecules into VP1-virus-like particles of the human polyomavirus JC virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Virus-like gene transfer into cells mediated by polyoma virus pseudocapsids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Interactions of heterologous DNA with polyomavirus major structural protein, VP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Persistence and tissue distribution of DNA in normal and immunodeficient mice inoculated with polyomavirus VP1 pseudocapsid complexes or polyomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Sustained ex vivo and in vivo transfer of a reporter gene using polyoma virus pseudocapsids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Enhancement by polylysine of transient, but not stable, expression of genes carried into cells by polyoma VP1 pseudocapsids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Mouse polyomavirus utilizes recycling endosomes for a traffic pathway independent of COPI vesicle transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

Liver-targeted gene therapy by SV40-based vectors using the hydrodynamic injection method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.7.997

21 January 2018

Identifiers

DOI

10.1517/14712598.7.7.997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17665989%20AND%20SRC:MED&resulttype=core&format=json

release_sdzqkyqqwrgvpgrcvtgeinod4y

2 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/sdzqkyqqwrgvpgrcvtgeinod4y

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference